Research programme: cancer therapeutics - Cloud Pharmaceuticals/University of Florida College of Medicine

Drug Profile

Research programme: cancer therapeutics - Cloud Pharmaceuticals/University of Florida College of Medicine

Alternative Names: 8-oxodGTPase inhibitors - Cloud Pharmaceuticals/University of Florida College of Medicine; MTH1 protein inhibitors - Cloud Pharmaceuticals/University of Florida College of Medicine; MutT homolog 1 protein inhibitors - Cloud Pharmaceuticals/University of Florida College of Medicine

Latest Information Update: 30 Apr 2015

Price : $50

At a glance

  • Originator Cloud Pharmaceuticals; University of Florida College of Medicine
  • Class Small molecules
  • Mechanism of Action 8-oxodGTPase inhibitors; Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Mar 2015 Cloud Pharmaceuticals and University of Florida College of Medicine enter into a collaboration for cancer therapeutics
  • 17 Mar 2015 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top